<DOC>
	<DOCNO>NCT00284804</DOCNO>
	<brief_summary>This study design determine objective response rate patient relapse refractory Hodgkin 's disease treat MDX-060 combination gemcitabine gemcitabine alone .</brief_summary>
	<brief_title>A Phase II Study MDX-060 Subjects With Relapsed Refractory Hodgkin 's Disease</brief_title>
	<detailed_description>Secondary objective include : - characterize progression-free survival - characterize time progression - determine response duration - characterize effect study drug health-related quality life - explore correlation positron emission tomography ( PET ) scan result objective response observe conventional imaging patient population - characterize immunogenicity response MDX-060 - characterize safety MDX-060 , - characterize pharmacokinetic profile MDX-060</detailed_description>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Diagnosis Hodgkin 's disease [ HD ] ( exclude HIVassociated HD ) Patients must read , understood , provide write informed consent Health Insurance Portability Accountability Act ( HIPAA ) authorization nature study fully explain Patients must fail relapse follow second line ( i.e. , salvage ) chemotherapy relapse fail follow autologous stem cell transplant ECOG Performance Status 02 Patients must bimeasurable disease At least 4 week since last chemotherapy radiation therapy clinical evidence recovery toxicity associate treatment Life expectancy 12 week great Screening laboratory value must meet Patients corticosteroid must taper medication 2 week prior study drug administration remain corticosteroid study completion . Previous treatment antiCD30 antibody History allogeneic transplant Any tumor lesion 10cm great diameter Any malignancy , exclude basal squamous cell carcinoma skin , cervical carcinoma situ . Any cancer patient disease free least 5 year permissible . Any significant active chronic infection Apparent active latent tuberculosis ( TB ) infection Patients pregnant nurse Any underlying medical condition , investigator 's opinion , make administration study drug hazardous obscure interpretation adverse event Concomitant chemotherapy , steroid , investigational agent , antiHD biologics , radiation therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>relapsed refractory Hodgkin 's Disease</keyword>
</DOC>